Research showed that the vaccine against late-stage pancreatic cancer has potential

• The ELI-002 2P vaccine demonstrated encouraging results in the study.
• 85% of participants showed an immune response to cancer.
• The median survival time for patients was 29 months.

The research indicated that the vaccine, which does not require personalization, may help combat relapses of late-stage pancreatic cancer and colorectal cancer. This vaccine, named ELI-002 2P, was tested on 25 patients, 20 of whom had late-stage pancreatic cancer.

The vaccine works by training immune cells to recognize and destroy cancer cells with mutations in the KRAS gene, which are present in 90% of cases of late-stage pancreatic cancer. After surgical treatment, patients received up to six doses of the vaccine, and 85% of them showed an immune response.

The results of the study showed that patients with a strong immune response had better chances of prolonged survival and a lower likelihood of cancer relapse. Among these patients, the median survival time was 29 months, while without relapses it was over 15 months.

The researchers emphasized that while the results are encouraging, the research is still in its early stages, and necessary further clinical trials are needed to confirm the effectiveness of the vaccine. The vaccine may prove to be cheaper and quicker to access than other therapies.

Tags: Research